Curbing the Delta Surge

• DOI: 10.1016/j.mayocp.2022.06.015
• Publication Date: 2022-06-23T04:58:25Z
• Authors: Raymund R. Razonable; John C. O’Horo; Douglas W. Challener; Lori Arndt; Richard F. Arndt; Caroline G. Clune; Tracy L. Culbertson; Scott T. Hall; Alexander Heyliger; Tammy A. Jackson; Brian D. Kennedy; Jennifer Larsen; Sara N. Hanson; Perry W. Sweeten; Sidna M. Tulledge...; Ravindra Ganesh
• Keywords: 03 medical and health sciences; 0302 clinical medicine

To describe and compare the clinical outcomes of bamlanivimab-etesevimab, casirivimab-imdevimab, sotrovimab treatment mild to moderate coronavirus disease 2019 (COVID-19) during severe acute respiratory 2 (SARS-CoV-2) B.1.617.2 Delta surge. This is a retrospective study high-risk patients who received for COVID-19 between August 1, 2021, December 2021. Rates disease, hospitalization, intensive care unit admission, death were assessed. Among 10,775 or surge, 287 (2.7%) developed that led oxygen supplementation, within 30 days after treatment. The rates low among treated with bamlanivimab-etesevimab (1.2%), casirivimab-imdevimab (2.9%), (1.6%; P<.01). higher rate may be related significantly lower vaccination in cohort. Intensive admission was comparable (1.0%, 1.0%, 0.4%, respectively). real-world large cohort shows mortality SARS-CoV-2